Thymalfasin for the treatment of chronic hepatitis C infection

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 6, 2005, Pages 885-892

  Rustgi, Vinod K ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus; Immunomodulating agents; Thymalfasin; Thymosin 1

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CANDESARTAN; CONSENSUS INTERFERON; CPG 10101; IMMUNOMODULATING AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAMIDINE; RIBAVIRIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG METABOLISM; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; INFERTILITY; INSOMNIA; KIDNEY INJURY; LIVER INJURY; MALAISE; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; PHARYNGITIS; PRURITUS; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; THYROID DISEASE; VIROLOGY; VIRUS LOAD; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; THYMOSIN;

EID: 28944433308     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.6.885     Document Type: Article

References (33)

1. 2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
2. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol. Clin. North Am. 33(1 Suppl.), S1-S9 (2004).
3. Moscarella S, Buzzelli G, Romanelli RG et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver 18, 366-369 (1998).
4. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am. J. Med. 117, 163-168 (2004).
5. Dantzler TE, Lawitz EJ. Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr. Gastroenterol. Rep. 5, 78-85 (2003).
6. Shiffman ML, Hoffman CM, Contos MJ et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117, 1164-1172 (1999).
7. 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27, 1128-1135 (1998).
8. 2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J. Gastroenterol. Hepatol. 19, S79-S81 (2004).
9. Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs 11, 515-528 (2002).
10. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485-1492 (1998).
11. Roferon-A® package insert. Hoffmann-LaRoche Inc., NJ, USA (2003).
12. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25, 591-598 (1996).
13. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
14. Gish RG, Arora S, Nelson D et al. End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon. Presented at 55th annual meeting of the American Association for the Study of Liver Diseases. October 29-November 2, MA, USA (2004).
15. Bacon B. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Dig. Dis. Week May 14-19, IL, USA (2005).
16. Afdhal N, Godofsky E, Dienstag J et al. Final Phase I/II trial results for NM 283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV infection, including previous interferon failures. Presented at 55th Annual Meeting of the American Association for the Study of Liver Diseases. October 29-November 2, MA, USA (2004).
17. Reesink H. Initial results of a Phase 1B, multiple-dose study of VX- 950, a hepatitis C virus protease inhibitor. Dig. Dis. Week IL, USA, May 14-19 (2005).
18. Lawrence M. A Phase 1, single-blind, dose-escalating study of the safety and pharmacokinetics of a single injection of pegylated interferon alfacon-1 in healthy volunteers. Dig. Dis. Week IL, USA, May 14-19 (2005).
19. Balasubramanian S. Angiotensin receptor blockage as an antifibrotic intervention in patients with chronic viral hepatitis C - a pilot study. Dig. Dis. Week IL, USA, May 14-19 (2005).
20. 1 after subcutaneous injection of three different formulations in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 37, 51-57 (1999).
21. 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30, 778-786 (2000).
22. 1 requires the TRAF6 signalling pathway. EMBO J. 6, 531-537 (2005).
23. 1 activates dendritic cells for fungal Th1 resistance through Toll-like receptor signaling. Blood 103, 4232-4239 (2004).
24. + cells in an in vitro thymic epithelia organ coculture model. Int. J. Immunopharmacol. 21, 15-26 (1999).
25. Andreone P, Cursaro C, Gramenzi A et al. A double-blind, placebo-controlled pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 16, 207-210 (1996).
26. 1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int. J. Immunopharmacol. 22, 1057-1066 (2000).
27. Colledge D. Paper presented at Second International Conference on Therapies for Viral Hepatitis, HI, USA (1997).
28. 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 39, 679-683 (1996).
29. 1 plus interferon-α for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J. Viral. Hepat. 11, 69-73 (2004).
30. 2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. J. Gastroenterol. Hepatol. 19, S76-S78 (2004).
31. 2a) and ribavirin in HCV non-responders: 48-week (end of therapy) results. Hepatology 40(Suppl. 1), 91A (2004).
32. 2a) and ribavirin in patients with chronic viral hepatitis C not responding to prior treatment: clinical experience with 40 Mexican patients. Presented at 2nd Annual Congress of the Mexican Association of Hepatology. Yucatan, Mexico, June 21-24 (2005).
33. SciClone Pharmaceuticals - data on file.